Antiplatelet and antithrombotic effect of F 16618, a new thrombin proteinase-activated receptor-1 (PAR1) antagonist
Open Access
- 13 September 2011
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 165 (6), 1827-1835
- https://doi.org/10.1111/j.1476-5381.2011.01668.x
Abstract
BACKGROUND AND PURPOSE New antithrombotic agents with the potential to prevent atherothrombotic complications are being developed to target receptors on platelets and other cells involved in plaque growth. The aim of this study was to investigate the antiplatelet effects of F 16618, a new non‐peptidic PAR1 (thrombin receptor) antagonist. EXPERIMENTAL APPROACH We investigated the inhibitory effect of F 16618 on human platelet aggregation ex vivo, in whole blood and washed platelets, by using a multiple‐electrode platelet aggregometer based on impedance and an optical aggregometer, respectively. Its effects on whole‐blood haemostasis (clot parameters) were analysed with the ROTEM thromboelastometry device and the platelet function analyser PFA‐100. A guinea‐pig model of arterial thrombosis was used to investigate its effects on thrombus formation in vivo. KEY RESULTS F 16618 inhibited PAR1 agonist peptide (SFLLR‐peptide)‐induced washed platelet aggregation ex vivo. This effect was concentration‐dependent and exhibited a competitive inhibition profile. Washed platelet aggregation, as well as P‐selectin expression induced by thrombin, were significantly inhibited by 10 µM F 16618. In whole‐blood experiments, 20 µM F 16618 inhibited SFLLR‐induced platelet aggregation by 49%. In contrast, it had no effect on whole‐blood haemostasis. In the guinea‐pig model of carotid thrombosis, 0.32 mg·kg−1 F 16618 doubled the occlusion time. CONCLUSIONS AND IMPLICATIONS F 16618 was shown to have strong antithrombotic activity in vivo and moderate antiplatelet effects ex vivo. As these effects were not associated with major effects on physiological haemostasis, this molecule is a good antiplatelet drug candidate for use either alone or in combination with current treatments.Keywords
This publication has 37 references indexed in Scilit:
- Guide to Receptors and Channels (GRAC), 5th editionBritish Journal of Pharmacology, 2011
- The novel and orally active thrombin receptor antagonist E5555 (Atopaxar) inhibits arterial thrombosis without affecting bleeding time in guinea pigsEuropean Journal of Pharmacology, 2011
- The roles and mechanisms of PAR4 and P2Y12/phosphatidylinositol 3‐kinase pathway in maintaining thrombin‐induced platelet aggregationBritish Journal of Pharmacology, 2010
- Role of Platelets in AtherothrombosisThe American Journal of Cardiology, 2009
- Cardiovascular Death and Nonfatal Myocardial Infarction in Acute Coronary Syndrome Patients Receiving Coronary Stenting Are Predicted by Residual Platelet Reactivity to ADP Detected by a Point-of-Care AssayCirculation, 2009
- Cross validation of the Multiple Electrode AggregometryThrombosis and Haemostasis, 2009
- The in-vitro effects of E5555, a protease-activated receptor (PAR)-1 antagonist, on platelet biomarkers in healthy volunteers and patients with coronary artery diseaseThrombosis and Haemostasis, 2009
- Proteinases and signalling: pathophysiological and therapeutic implications via PARs and moreBritish Journal of Pharmacology, 2008
- Prasugrel versus Clopidogrel in Patients with Acute Coronary SyndromesNew England Journal of Medicine, 2007
- Par4 is required for platelet thrombus propagation but not fibrin generation in a mouse model of thrombosisProceedings of the National Academy of Sciences of the United States of America, 2007